Amneal’s Generic Lanreotide Wins FDA Clearance, Shares Surge

The Food and Drug Administration just gave the green light to Amneal’s 120‑milligram lanreotide prefilled syringe – essentially a generic twin of Ipsen’s long‑acting Somatulose Depot. It’s the kind of news that makes traders sit up and take notice.

Doctors use the original Somatuline Depot to tamp down excess growth hormone in acromegaly, slow the growth of certain gut and pancreatic neuro‑endocrine tumors, and quiet the flare‑ups of carcinoid syndrome. In the 12 months ending July, Ipsen raked in roughly $983 million in U.S. sales, according to IQVIA data.

What makes Amneal’s win even sweeter is the FDA’s decision to tag the product with “Competitive Generic Therapy” status. That label is meant to fast‑track generics that face thin competition, giving them a bit of a runway to capture market share sooner rather than later.

Shares of Amneal Pharmaceuticals (AMRX) reacted almost instantly. After the bell on Friday, the stock closed at $18.71 – up 2.35 % during regular trading – and then nudged another 2 % higher in after‑hours, touching $19.17. Investors seem to be betting on a market that hovers close to the $1 billion mark.

This isn’t a surprise win out of the blue. Amneal’s pipeline disclosures had already hinted at a third‑quarter 2026 decision. During the July earnings call, co‑CEO Chirag Patel warned that the filing had a “formal goal date” in the quarter and that modest sales were already baked into the forecast.

For Amneal, the launch is more than just another line‑extension. It’s a hard‑to‑make injectable that the company produces in‑house, part of its “Affordable Medicines” strategy. Srinivas Kone, the unit’s chief scientific officer, said the firm can supply the drug at scale and hopes it becomes a growth engine.

Competitors are already in the arena – Cipla’s InvaGen unit, for example, has its own lanreotide version on the market. Still, the FDA’s Competitive Generic Therapy designation could give Amneal a modest edge.

On the retail side, chatter on Stocktwits remained cautiously bearish over the past 24 hours, even as message volume stayed high. Still, AMRX is up about 48 % year‑to‑date, underscoring a broader optimism around its pipeline.

Investors and analysts will be watching closely to see how quickly Amneal can convert this regulatory win into real‑world prescriptions. For now, the market has spoken – a modest but clear vote of confidence.